Journal
/
/
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
JoVE Journal
Cancer Research
A subscription to JoVE is required to view this content.  Sign in or start your free trial.
JoVE Journal Cancer Research
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
DOI:

08:12 min

October 05, 2020

, , , , ,

Chapters

  • 00:05Introduction
  • 00:26Preparation of a Synchronous C. elegans Culture
  • 02:51Preparation of Drug Assays
  • 04:30Observation of the Muv Phenotype in the let-60, let-23 and lin-1 Strains
  • 06:38Results: R-fendiline Alters let-60 and let-23 Function in C. elegans in a Dose-dependent Manner
  • 07:25Conclusion

Summary

Automatic Translation

The genetically tractable nematode Caenorhabditis elegans can be used as a simple and inexpensive model for drug discovery. Described here is a protocol to identify anticancer therapeutics that inhibit the downstream signaling of RAS and EGFR proteins.

Related Videos

Read Article